Volgens de overeenkomst, die China uitsluit, zal Pfizer $ 1,25 mld. betalen en een investering van $ 100 mln. doen in het ...

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

The deal, which excludes China but provides Pfizer with an option for commercialization rights within the country, involves an upfront payment of $1.25 billion to 3SBio.

NEW YORK - Pfizer Inc. (NYSE:PFE), a pharmaceutical giant with $62.46 billion in revenue and a market capitalization of $130.76 billion, has secured an exclusive licensing agreement with Chinese ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer also has an option to obtain commercialization rights in China. Separately, Pfizer said it plans to invest $100 million in 3SBio equity after the licensing deal closes, which is expected in ...

3SBio shares jumped 36.4% to HK$19.78 by the afternoon break, compared to an over 1% jump in the Hang Seng index. Pfizer said on Tuesday that it had signed an agreement with 3SBio to license its ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...